Classes
DEA Class; Rx
Common Brand Names; Nesacaine, Clorotekal
- Local Anesthetics, Esters;
- Local Anesthetics, Parenteral
Description
Short-acting ester-type local anesthetic
Used for infiltration anesthesia; peripheral, sympathetic, epidural, caudal, subarachnoid, intravenous regional (Bier’s method) blocks; and ocular surface anesthesia
Not effective as a topical anesthetic
Indications
Indicated for regional anesthesia.
For local anesthesia via infiltration anesthesia or nerve block anesthesia.
Contraindications
Hypersensitivity to para-aminobenzoic acid (PABA) or parabens
Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: Existing neurological disease, spinal deformities, septicemia, and severe hypertension
General and specific contraindications to spinal anesthesia regardless of the local anesthetic use, should be taken into account (eg, decompensated cardiac insufficiency, hypovolemic shock, coagulopathy)
IV regional anesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area)
Serious problems with cardiac conduction
Local infection at the site of proposed lumbar puncture
Septicemia
Adverse Effects
Procedural pain (16%)
Hypotension (4.9%)
Injection site pain (3.7%)
Common
Anxiety
Dizziness
Restlessness
Tremor
Tinnitus
Blurred vision
Rare (serious)
Bradyarrhythmia
Cardiac arrest
Hypotension
Excitation
Depression
Seizure
Anaphylaxis
Respiratory arrest
Warnings
Local anesthetics should only be administered by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies
Hypotension and bradycardia are well known side effects of all local anesthetics
Neurological damage may occur after spinal anesthesia, manifesting as paresthesia, loss of sensitivity, motor weakness, paralysis, cauda equina syndrome; occasionally these symptoms persist and can be permanent
Use extreme caution with lumbar and caudal epidural anesthesia in person with existing neurological disease, spinal deformities, septicemia, severe hypertension, heart block, high grade cardiac decompensation, advanced liver or kidney impairment, elderly patients and patients in poor general condition, genetic cholinesterase deficiency, severe anemia, congenital or acquired bleeding disorder, and patients taking anticoagulants
Use preservative free preparations for spinal or epidural anesthesia
DO NOT use solutions with epinephrine in distal areas of body (eg, digit, nose, ear)
Addition of vasoconstrictor, epinephrine, will promote local hemostasis, decrease systemic absorption, and increase duration of action
Monitor patient’s state of consciousness following the injection; anxiety, dizziness, restlessness, tremors, depression, or blurred vision may be signs of CNS toxicity
Chondrolysis associated with intra-articular infusions following arthroscopic and other surgical procedures (off-label use)
Hypersensitivity reactions reported; cross-reactivity among ester-type local anesthetics may occur (see Contraindications)
Respiratory arrest reported with local anesthetics
Pregnancy and Lactation
Data are limited regarding use in pregnant women
Data are not available on the presence of chloroprocaine in human milk, the effects on the breastfed infant, or the effects on milk production
The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition
Maximum Dosage
The dose of local anesthetics differs with the anesthetic procedure; the area to be anesthetized; the vascularity of the tissues; the number of neuronal segments to be blocked; the intensity of the block; the degree of muscle relaxation required; the duration of anesthesia desired; individual tolerance; and the physical condition of the patient.
50 mg/dose intrathecally; 11 mg/kg for other parenteral routes, not to exceed 800 mg/dose when given without epinephrine. With epinephrine (1:200,000), 14 mg/kg, not to exceed 1,000 mg. 3 drops/dose for ophthalmic gel.
50 mg/dose intrathecally. 11 mg/kg for other parenteral routes, not to exceed 800 mg/dose when given without epinephrine. With epinephrine (1:200,000), 14 mg/kg, not to exceed 1,000 mg. 3 drops/dose for ophthalmic gel.
11 mg/kg. Concentrations of 0.5% to 1% are suggested for infiltration, and 1% to 1.5% are recommended for nerve block. Safety and efficacy of the ophthalmic gel and intrathecal chloroprocaine have not been established.
4 years and older: 11 mg/kg. Concentrations of 0.5% to 1% are suggested for infiltration, and 1% to 1.5% are recommended for nerve block. Safety and efficacy of the ophthalmic gel and intrathecal chloroprocaine have not been established.
3 years and younger: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Chloroprocaine Hydrochloride
solution, injection for nerve block
- 1% (Nesacaine)
- 2% (Nesacaine, Nesacaine MPF [preservative free])
- 3% (Nesacaine MPF)
solution, intrathecal injection
- 10mg/mL (Clorotekal)
- Supplied as 50mg/5mL chloroprocaine HCl (equivalent to 44.05mg/5mL [8.81mg/mL] chloroprocaine)